First-in-man clinical trial to assess safety and tolerability of CEB-01 PLGA membrane in patients with recurrent or locally advanced retroperitoneal soft tissue sarcoma after surgery

2024-516971-34-00 Protocol CEB-01-RLS01-CT Human pharmacology (Phase I) - First administration to humans Ended

Start 20 Aug 2024 · End 28 Nov 2025 · Status Ended · 1 EU/EEA countries · 5 sites · Protocol CEB-01-RLS01-CT

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ended
Participants planned 21
Countries 1
Sites 5

Recurrent or locally advanced retroperitoneal soft tissue sarcoma

Key facts

Sponsor
Cebiotex S.L.
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
20 Aug 2024 → 28 Nov 2025
Decision date (initial)
2024-08-20
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

External identifiers

EU CT number
2024-516971-34-00
EudraCT number
2018-001026-25
ClinicalTrials.gov
NCT04619056

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Recurrent or locally advanced retroperitoneal soft tissue sarcoma

VersionLevelCodeTermSystem organ class
20.0 PT 10039491 Sarcoma 100000004864

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Cebiotex S.L.

Sponsor organisation
Cebiotex S.L.
Address
Tech Barcelona Pier 07 Entresuelo, Via Laietana 26 Via Laietana 26
City
Barcelona
Postcode
08003
Country
Spain

Scientific contact point

Organisation
Cebiotex S.L.
Contact name
Anna Huguet

Public contact point

Organisation
Cebiotex S.L.
Contact name
MFAR Clinical Research

Locations

1 EU/EEA country · 5 investigational sites

By country

CountryMS statusPlanned subjectsSites
Spain Ended 21 5
Rest of world 0

Investigational sites

Spain

5 sites · Ended
Hospital De La Santa Creu I Sant Pau
Oncology, Carrer De San Quinti 89, 08041, Barcelona
Hospital Universitario Y Politecnico La Fe
Oncology, Avenida De Fernando Abril Martorell 106, 46026, Valencia
Hospital Universitario Fundacion Jimenez Diaz
Oncology, Avenida De Los Reyes Catolicos 2, 28040, Madrid
Hospital Universitari Vall D Hebron
Oncology, Passeig De La Vall D'Hebron 119-129, 08035, Barcelona
Hospital General Universitario Gregorio Maranon
Oncology, Calle Del Doctor Esquerdo 46, 28007, Madrid

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Spain 2024-08-20 2025-11-28 2024-08-20 2024-08-20

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-08-06 Spain Acceptable with conditions
2024-08-20
2024-08-20